China: New Horizon Health raises HK$780m from share placement

New Horizon Health, a commercial-stage biotech company principally engaged in developing and commercialising innovative cancer screening products, has raised around HK$780m from a share placement. It placed 27.5 million shares (approximately 6.4% of the issued share capital/6.02% of the enlarged share capital) at a price of HK$28.38, representing a discount of 8% to the HK$30.85…